Amgen Inc. AMGN
Loading live quote…
$354.06
+16.33
(+4.84%)
Price Chart
About Amgen Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp…
Recent Quarters
| Quarter | Revenue | Net Income | EPS (dil.) | Gross Margin |
|---|---|---|---|---|
| 2026 Q1 | — | $1.82B | 3.34 | 68.2% |
| 2025 Q4 | — | $1.33B | 2.45 | 69.8% |
| 2025 Q3 | — | $3.22B | 5.93 | 67.8% |
| 2025 Q2 | — | $1.43B | 2.65 | 67.2% |
AMGN — Latest Coverage
